0001213900-22-030181.txt : 20220527 0001213900-22-030181.hdr.sgml : 20220527 20220527172241 ACCESSION NUMBER: 0001213900-22-030181 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220524 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220527 DATE AS OF CHANGE: 20220527 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viveon Health Acquisition Corp. CENTRAL INDEX KEY: 0001823857 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39827 FILM NUMBER: 22979041 BUSINESS ADDRESS: STREET 1: C/O GIBSON, DEAL, AND FLETCHER, P. C. STREET 2: 3953 CITY: NORCROSS STATE: GA ZIP: 30092 BUSINESS PHONE: 4045797978 MAIL ADDRESS: STREET 1: C/O GIBSON, DEAL, AND FLETCHER, P. C. STREET 2: 3953 CITY: NORCROSS STATE: GA ZIP: 30092 8-K 1 ea160741-8k_viveon.htm CURRENT REPORT
0001823857 false 0001823857 2022-05-24 2022-05-24 0001823857 VHAQ:UnitsMember 2022-05-24 2022-05-24 0001823857 us-gaap:CommonStockMember 2022-05-24 2022-05-24 0001823857 VHAQ:WarrantsMember 2022-05-24 2022-05-24 0001823857 us-gaap:RightsMember 2022-05-24 2022-05-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Form 8-K

 

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

May 24, 2022

Date of Report (Date of earliest event reported)

 

Viveon Health Acquisition Corp.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-39827   85-2788202
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

c/o Gibson, Deal & Fletcher, PC

Spalding Exchange

3953 Holcomb Bridge Road

Suite 200

Norcross Georgia

   30092
(Address of Principal Executive Offices)   (Zip Code)

  

Registrant’s telephone number, including area code: (404) 861-5393

 

N/A
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Units   VHAQ.U   NYSE American, LLC
Common Stock   VHAQ   NYSE American, LLC
Warrants   VHAQ.WS   NYSE American, LLC
Rights   VHAQ.R   NYSE American, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

As previously reported in a Form 12b-25 Notification of Late Filing filed by Viveon Health Acquisition Corp. (the “Company”) on May 16, 2022, the Company is delayed in filing with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the “Form 10-Q”) because the financial statements could not be completed in sufficient time to solicit and obtain the necessary review of the Form 10-Q in a timely fashion prior to the due date of the report.

 

As of May 23, 2022, the Company remained unable to file the Form 10-Q. As a result, on May 24, 2022, in accordance with standard procedures related to the delayed filing of the Form 10-Q with the SEC, the Company received a late filer notification from the New York Stock Exchange (the “NYSE”) stating that the Company is not in compliance with the NYSE American’s continued listing requirements under the timely filing criteria established in the NYSE American Company Guide. Under Section 1007 of the NYSE American Company Guide, the Company could be granted up to 12 months to cure the late filer deficiency. The initial six month period to regain compliance is automatic and the additional six months is only granted upon request by the Company and approval by the NYSE. The NYSE notice has no immediate effect on the listing or trading of the Company's securities on the NYSE American.

 

The Company anticipates that it will fully regain compliance with the NYSE American’s continued listing requirements upon filing its Form 10-Q.

 

A press release, dated May 27, 2022, disclosing the Company's receipt of the NYSE notification letter is attached as Exhibit 99.1 and is furnished herewith.

 

Item 9.01. Financial Statements and Exhibits.

 

  (d) Exhibits

 

99.1 Press Release, dated May 27, 2022.
104Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL Document

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 27, 2022  
   
VIVEON HEALTH ACQUISITION CORP.  
   
By: /s/ Jagi Gill  
Name:  Jagi Gill                                                                
Title: Chief Executive Officer  

 

 

2

 

 

 EX-99.1 2 ea160741ex99-1_viveon.htm PRESS RELEASE, DATED MAY 27, 2022

Exhibit 99.1

 

Viveon Health Acquisition Corp. Receives Noncompliance Notice

Regarding Late Form 10-Q Filing From the NYSE

 

New York, May 27, 2022 /GLOBE NEWSWIRE/ -- Viveon Health Acquisition Corp. (NYSE: “VHAQU” or the “Company”) announces that on May 24, 2022, as a result of its inability to timely file with the Securities and Exchange Commission ("SEC") its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022 (the "Form 10-Q"), it received a notice from the New York Stock Exchange (the "NYSE") stating that the Company is not in compliance with the NYSE American’s continued listing requirements under the timely filing criteria established in the NYSE American Company Guide. Under the Section 1007 of the NYSE American Company Guide, the Company could be granted up to 12 months to cure the late filer deficiency. The initial six month period to regain compliance is automatic and the additional six months is only granted upon request by the Company and approval by the NYSE. The NYSE notice has no immediate effect on the listing or trading of the Company's securities on the NYSE American.

 

As previously disclosed by the Company in its Form 12b-25 filed with the SEC on May 16, 2022, the Company was unable to file its Form 10-Q by its original deadline without unreasonable effort or expense due to the fact that the financial statements could not be completed in sufficient time to solicit and obtain the necessary review of the Form 10-Q in a timely fashion prior to the original due date of the report. The Company is still working to complete certain disclosure regarding the financial information in the Form 10-Q and expects that it will file the Form 10-Q no later than June 10, 2022. However, the timing of the filing is uncertain at this moment, and this projected filing date could change.

 

About Viveon Health Acquisition Corp.

 

Viveon Health Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

 

Forward-Looking Statements

 

This press release contains certain forward-looking statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "seeks," "projects," "intends," "plans," "may," "will" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this press release and include statements regarding our intentions, beliefs or current expectations concerning the Company's performance, business and future events, including its ability to file the Form 10-Q and the attendant consequences with the SEC and NYSE and the continued listing of the Company's securities on the NYSE American. Such forward looking statements are based on management's expectations, beliefs and forecasts concerning future events impacting Viveon Health. You are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, as well as assumptions, which, if they were to ever materialize or prove incorrect, could cause actual results to differ materially from the from the plans, objectives, expectations, estimates and intentions expressed or implied by such forward-looking statements. The forward-looking statements made in this press release speak only as of the date hereof and we disclaim any obligation, except as required by law, to provide updates, revisions or amendments to any forward-looking statements to reflect changes in our expectations or future events.

 

Contact:
Rom Papadopoulos
CFO, Viveon Health Acquisition Corp.
404-861-5393

 

 

 EX-101.DEF 3 vhaq-20220524_def.xml XBRL DEFINITION FILE EX-101.LAB 4 vhaq-20220524_lab.xml XBRL LABEL FILE Class of Stock [Axis] Units Common Stock [Member] Warrants Rights [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 vhaq-20220524_pre.xml XBRL PRESENTATION FILE EX-101.SCH 6 vhaq-20220524.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 24, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date May 24, 2022
Entity File Number 001-39827
Entity Registrant Name Viveon Health Acquisition Corp.
Entity Central Index Key 0001823857
Entity Tax Identification Number 85-2788202
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One c/o Gibson, Deal & Fletcher, PC
Entity Address, Address Line Two 3953 Holcomb Bridge Road
Entity Address, Address Line Three Suite 200
Entity Address, City or Town Norcross
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30092
City Area Code (404)
Local Phone Number 861-5393
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units  
Title of 12(b) Security Units
Trading Symbol VHAQ.U
Security Exchange Name NYSEAMER
Common Stock [Member]  
Title of 12(b) Security Common Stock
Trading Symbol VHAQ
Security Exchange Name NYSEAMER
Warrants  
Title of 12(b) Security Warrants
Trading Symbol VHAQ.WS
Security Exchange Name NYSEAMER
Rights [Member]  
Title of 12(b) Security Rights
Trading Symbol VHAQ.R
Security Exchange Name NYSEAMER
XML 8 ea160741-8k_viveon_htm.xml IDEA: XBRL DOCUMENT 0001823857 2022-05-24 2022-05-24 0001823857 VHAQ:UnitsMember 2022-05-24 2022-05-24 0001823857 us-gaap:CommonStockMember 2022-05-24 2022-05-24 0001823857 VHAQ:WarrantsMember 2022-05-24 2022-05-24 0001823857 us-gaap:RightsMember 2022-05-24 2022-05-24 iso4217:USD shares iso4217:USD shares 0001823857 false 8-K 2022-05-24 Viveon Health Acquisition Corp. DE 001-39827 85-2788202 c/o Gibson, Deal & Fletcher, PC 3953 Holcomb Bridge Road Suite 200 Norcross GA 30092 (404) 861-5393 false false false false Units VHAQ.U NYSEAMER Common Stock VHAQ NYSEAMER Warrants VHAQ.WS NYSEAMER Rights VHAQ.R NYSEAMER true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( -.*NU0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #3BKM4UI>!K^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*'%8!R;UI:.G#@8K;.QF;+4UBQUC:R1]^SE9FS*V!]C1TN]/ MGT"M#D+W$9]C'S"2Q70WNLXGH<.:G8B" $CZA$ZE,B=\;A[ZZ!3E9SQ"4/I# M'1%X5:W (2FC2,$$+,)"9+(U6NB(BOIXP1N]X,-G[&:8T8 =.O24H"YK8'*: M&,YCU\(-,,$(HTO?!30+<:[^B9T[P"[),=DE-0Q#.31S+N]0P]O3[F5>M[ ^ MD?(:\Z]D!9T#KMEU\FNS>=QOF>05YT5U7_"'/:\%YZ)9O4^N/_QNPJXW]F#_ ML?%54+;PZR[D%U!+ P04 " #3BKM4F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M -.*NU0TN/I?1 4 %<8 8 >&PO=V]R:W-H965T&UL MI9EO4^)($,9?KY]BBA=7NU4JR404]I J1/Q3N[J=]I,F$@;O6Y^;*1Z79F96*1\I(C. MDH2I]06/Y>J\X3?>#CR(^<+8 \U>=\GF?,S-XW*D8*]9J$0BX:D6,B6*S\X; M??_S1="Q ?D93X*O],XVL9)>(Q#XV58/#GA0]X'%LEX/BQ M%6T4WVD#=[??U*_RBX>+F3+-!S)^%I%9G#?:#1+Q&)V D(3O<$T&T S;DW7Y137C+#>ETE M5T39LT'-;N27FD<#G$CMJHR-@D\%Q)G>0+YPU6T:D+('FN$V[&(31O>$W;$U MH2>'A'J4_C.Z"0 %!2TH:"X7[)&[E&$&2VW(9+WD931X>/OH"P(1%! !JM(' M@BBGN(K9O(P"CY^Q6'.$XZ3@.*F7C!%70D9DF$8$UK8T+[C2=I4./GRH6*=6 M@=9"!8>I$69-KD3,R7V63,M+!]?P//\HZ+3I&<)S6O"PKHK%Y#:-^"OY MPM=EK+B2!PELTZ#=PA+8+K#:=; F[)7<1L F9B)D^87O7UY^I:5@%9)A4QX0^+D64VTO^!+JDOS"DN6O8$W<0&=6AV0T MP/!W_-__[_B3E2S%QR6#3BO(^6]D',ID2BZ4B.:(X-$PV&Z?J)CS>$GS$'=@_*=B)7:2D@+GM_5L(8;GMFDF3IMI'H4BIS_>[B@SODI[M*/J3!8#Z'. MJ"ENJQ-AX#E SHA//TX_D3$/,W" \J7 E2J9G$%3W%\AUY&MCO$ZF[U" MX.FF_]OQ(\;B')KBYOJ6$*B$<,%2F(#V/9U4"-W_/A[V[X8/&)5S:8J;JW5G MJ,2QD>%W\N<=MYWC+TS9F2W%;?(]]8 K;1CS82SGQ)[NG?<&N%=6ET:%@"T- MC,1Y;8";8OW"J!"J41B!,]@ ]\-GINPC-'8?!COO4G"_>D4 2Y4IPR<@P:X >8O9G4=9PB<$P:X@;VG&G"E M#1T&Y8PPP(VP1BW@ GDMH$EWUAE4S*GU2P$7PDJAN?.:V+YROV-VDM(DYC/0 M\H[/H,K4YBWV9L?(9?[F>"J-D4F^N> ,QD%[ GP^D]*\[=B7T<7_$GI_ U!+ M P04 " #3BKM4X/0ZB:H" P# #0 'AL+W-T>6QE&:.9N:,9F235>/.DC\>.7>D4U(W:WITKGZ?),WAR!5KWIB::X^4QBKFO&JK MI*DM9T4#3DHFB]DL2Q03FFY6NE4[Y1IR,*UV:SJCR695&GVQI#08_%*F.#DQ MN:9;)L7>BGXM4T*>@WD!AH.1QA+GJ? UG8.E>0[P/&C 2T(M/!;2!0*FCZ D-8@@3%(A_'2W$O@K[]J_"DEJ,/EI>BZ_6NG/)CT>=X=%;7\OQ!BDHK'FK_[82;%1O]R-%8\>RSP:0*:6R:O2?O1CS-.AEF\&OB;<9^L M!!XK:_H5GE;RPH'L6R&=T(-V%$7!]8NI]^$=V_O'X4U\O[[@)6NE>YK -;W( M7W@A6I5/JQY@7X95%_DSG.YY-CW3?"ZA"][Q8CNHMMKW(O&"SSI@*&<5M&D27JLT1]@E<,V?8?+$_<)_=7 MO-(\3],LPW9TNXTRV&+[EF7PC4?#N($'E@X]W&)^3U.6!>PV8'\\3PP4W&?-(6N8MRP$XPC>8XA,(OQ M&-8?20$3;8T.P6BP^0"X9 M9K>]9!:G% MC:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z* M0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,Z ME._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8 M,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0] MC.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\ MGN4/4$L#!!0 ( -.*NU0D'INBK0 /@! : >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X* MMR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>L MXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " #3BKM499!YDAD! #/ P $P %M#;VYT96YT M7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+; M,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R: MMB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT* M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87 M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( -.*NU0'04UB@0 M +$ 0 " 0 !D;V-0&UL4$L! A0# M% @ TXJ[5-:7@:_N *P( !$ ( !KP &1O8U!R M;W!S+V-O&UL4$L! A0#% @ TXJ[5)E&PO=V]R:W-H965T M&UL4$L! A0#% @ TXJ[5.#T.HFJ @ , P T M ( !APT 'AL+W-T>6QE&PO=V]R M:V)O;VLN>&UL4$L! A0#% @ TXJ[5"0>FZ*M ^ $ !H M ( !I1( 'AL+U]R96QS+W=O9(9 0 SP, !, ( !BA, %M#;VYT96YT A7U1Y<&5S72YX;6Q02P4& D "0 ^ @ U!0 end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 5 25 1 false 4 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://viveonhealthacquisitioncorp.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea160741-8k_viveon.htm ea160741ex99-1_viveon.htm vhaq-20220524.xsd vhaq-20220524_def.xml vhaq-20220524_lab.xml vhaq-20220524_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea160741-8k_viveon.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 5, "dts": { "definitionLink": { "local": [ "vhaq-20220524_def.xml" ] }, "inline": { "local": [ "ea160741-8k_viveon.htm" ] }, "labelLink": { "local": [ "vhaq-20220524_lab.xml" ] }, "presentationLink": { "local": [ "vhaq-20220524_pre.xml" ] }, "schema": { "local": [ "vhaq-20220524.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 67, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 2, "memberStandard": 2, "nsprefix": "VHAQ", "nsuri": "http://viveonhealthacquisitioncorp.com/20220524", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea160741-8k_viveon.htm", "contextRef": "From2022-05-24to2022-05-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://viveonhealthacquisitioncorp.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea160741-8k_viveon.htm", "contextRef": "From2022-05-24to2022-05-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 4, "tag": { "VHAQ_UnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Units" } } }, "localname": "UnitsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20220524", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "VHAQ_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "WarrantsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20220524", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_RightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights [Member]" } } }, "localname": "RightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001213900-22-030181-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-030181-xbrl.zip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end